Anna Rose Welch
Click here to e-mail Anna Rose
Anna Rose Welch is the director of Cell & Gene Collaborative. In this role, she is forging close relationships with the leading voices and organizations in the cell and gene therapy manufacturing sphere. This includes establishing a peer group comprising Cell & Gene company manufacturing SMEs, conducting interviews and hosting interactive roundtables on the evolving manufacturing paradigm, and authoring thought leadership articles and blog posts via the Cell & Gene Collaborative blog.
Prior to launching Cell & Gene Collaborative, Anna Rose spent five years building an extensive network and editorial following as the Chief Editor of Biosimilar Development. In addition to penning thought leadership on biosimilar regulatory affairs, government policy, and commercialization advances, she was also an active participant in the biosimilar conferences circuit. She was appointed chair or served as a speaker and panel moderator at international conferences, including the World Biosimilar Congress USA, The Biotech Pharma Summit (EU), the CBI Biosimilars Summit, DIA Biosimilars Conference, and the Biosimilar Medicines Group Conference (EU). In 2018, she was invited to Brazil where she addressed members of the Brazilian Ministry of Health, ANVISA, and local biologics and biosimilar manufacturers on establishing national biologics and biosimilar policies. She also represented the publication on a media tour of Bangkok, Thailand in 2017, during which she reported on the country’s efforts to bolster its life sciences industry. In addition to writing for Biosimilar Development, she penned the introductory chapter to the book, Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (Springer, 2018).
In 2018, her first book of poetry, We, The Almighty Fires, was published by Alice James Books.
ARTICLES BY ANNA ROSE
-
![R&D]( "A Glimpse Into Thailand’s Ongoing Life Sciences Transformation")
A Glimpse Into Thailand’s Ongoing Life Sciences Transformation5/18/2017During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.
-
![R&D]( "What Thailand Revealed About U.S. Pharma R&D")
What Thailand Revealed About U.S. Pharma R&D5/16/2017A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.
-
![Biosimilar industry]( "Top 5 Biosimilar Developments Of 2016")
Top 5 Biosimilar Developments Of 201612/29/2016In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.
-
![biosimilar industry]( "The Case For Moving The EMA To Ireland")
The Case For Moving The EMA To Ireland12/13/2016Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.
-
![biosimilar industry]( "Will Teva’s Play Usher Generic, Biosimilar Makers Into “Innovator” Territory?")
Will Teva’s Play Usher Generic, Biosimilar Makers Into “Innovator” Territory?7/7/2016PhRMA is facing a controversial, potentially industry-altering decision. The generics king Teva has requested to become a member of the trade organization that traditionally represents “innovators”. Could this move redefine the industry's perception of "innovation"?
-
![Biosimilar industry]( "What Biosimilars Can Learn From The Diamond Industry")
What Biosimilars Can Learn From The Diamond Industry7/5/2016Not only are there some fascinating parallels between the fledging biosimilar and lab-grown diamond industries, but there are also some lessons biosimilar makers can take away from the development and commercialization of lab-grown diamonds.
-
![drug pricing]( "Could Value-Based Pricing Be Yet Another Roadblock To Biosimilar Uptake?")
Could Value-Based Pricing Be Yet Another Roadblock To Biosimilar Uptake?3/3/2016As pay-for-performance drugs becomes more high-profile in the U.S., these emerging deals pose a number of difficulties for reference makers. But if pay-for-performance becomes more wide-spread, could innovators' successes become yet another roadblock to getting biosimilars into doctor's treatment repertoire and patients' hands?
-
![EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market]( "EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market")
EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market1/12/2016Though differentiating large-molecule biosimilars from small molecule generics is a staple in biosimilar education, Amit Munshi, CEO of pure-play biosimilar company EPIRUS Biopharmaceuticals, argues the history of the generics market could hold valuable clues as to how the biosimilar market will evolve.
-
![generic drugs]( "The Generic And Biosimilar Markets: Are They Really That Different?")
The Generic And Biosimilar Markets: Are They Really That Different?10/19/2015As the FDA continues to compose guidances on the labeling and interchangeability of biosimilar medicines, there remains one big, overarching concern in the industry, and that is making sure biosimilar medicines are not treated as small molecule generics. But should we really be considering the two types of drugs as drastically different as we have been over the past few months?
-
![drug approvals]( "Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market?")
Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market?9/1/2015Last week, Matthew Herper of Forbes published an eye-opening article providing a closer look at FDA approvals in recent years, coming to the conclusion that the industry is facing what could be a dangerously high approval rate for new drugs. But how could high approval rates be a bad thing?
